Drug Profile
CNTO 5825
Alternative Names: CNTO-5825; Human monoclonal antibody (CNTO 5825) - CentocorLatest Information Update: 31 Mar 2016
Price :
$50
*
At a glance
- Originator Centocor Ortho Biotech
- Developer Janssen Biotech
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 22 Jun 2011 Centocor Ortho Biotech is now called Janssen Biotech
- 30 Sep 2010 Centocor completes a phase I trial in Allergic asthma in Belgium
- 31 Jan 2010 Phase-I clinical trials in Allergic asthma in Belgium (SC)